NCX1000

Known as: NCX 1000, NCX-1000 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2001-2009
012320012009

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
OBJECTIVES:NCX-1000 (2(acetyloxy) benzoic acid-3(nitrooxymethyl)phenyl ester) is an nitric oxide (NO)-releasing derivative of… (More)
  • table 1
  • figure 2
  • table 2
  • figure 1
  • table 3
Is this relevant?
2007
2007
Nonalcoholic steatohepatitis (NASH) is a common and potentially severe form of liver disease. This study aimed to determine the… (More)
Is this relevant?
2004
2004
1. NCX-1000, (3alpha, 5beta, 7beta)-3,7-dihydroxycholan-24oic acid[2-methoxy-4-[3-[4-(nitroxy)butoxy]-3-oxo-1-propenyl]phenyl… (More)
Is this relevant?
Review
2004
Review
2004
Portal hypertension, a life threatening complication of liver cirrhosis, results from increased intrahepatic resistance and… (More)
Is this relevant?
2003
2003
BACKGROUND/AIMS A decreased intra-hepatic nitric oxide (NO) production participates on the pathogenesis of portal hypertension in… (More)
Is this relevant?
2003
2003
BACKGROUND/AIMS We studied whether acute administration of NCX-1000, a nitric oxide (NO)-releasing derivative of ursodeoxycholic… (More)
Is this relevant?
2003
2003
Portal hypertension, a common consequence of chronic liver diseases, is directly responsible for most complications of cirrhosis… (More)
Is this relevant?
2001
2001
Portal hypertension resulting from increased intrahepatic resistance is a common complication of chronic liver diseases and a… (More)
Is this relevant?
2001
2001
Caspases are key mediators in liver inflammation and apoptosis. In the present study we provide evidence that a nitric oxide (NO… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?